Forte Biosciences (FBRX) Accumulated Expenses (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Accumulated Expenses of $10.6 million for Q1 2026, up 745.04% year-over-year from $1.2 million in Q1 2025, and up 369.47% quarter-over-quarter from $2.2 million in Q4 2025.
Forte Biosciences (FBRX) Accumulated Expenses (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Accumulated Expenses for 11 consecutive years, with $10.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 745.04% year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $10.6 million (up 745.04% YoY), while the FY2025 annual figure was $2.2 million, up 45.07% from the prior year.
- Accumulated Expenses rose to $10.6 million in Q1 2026 per FBRX's latest filing, from $2.2 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $10.6 million in Q1 2026 and bottomed at $359000.0 in Q1 2022.
- Historically, Accumulated Expenses has averaged $2.2 million across 5 years, with a median of $1.6 million in 2024.
- Annual changes were most pronounced in 2022 — Accumulated Expenses tumbled 77.22% — and 2026, when it jumped 745.04%.
- Forte Biosciences' Accumulated Expenses stood at $2.0 million in 2022, then tumbled by 53.26% to $947000.0 in 2023, then jumped by 63.78% to $1.6 million in 2024, then jumped by 45.07% to $2.2 million in 2025, then jumped by 369.47% to $10.6 million in 2026.
- Business Quant data shows FBRX's Accumulated Expenses at $10.6 million in Q1 2026, $2.2 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.28 Mn |
| Mar 31, 2026 | 10.56 Mn |
| Dec 31, 2025 | 2.25 Mn |
| Sep 30, 2025 | 1.33 Mn |
| Jun 30, 2025 | 934,000.00 |
| Mar 31, 2025 | 1.25 Mn |
| Dec 31, 2024 | 1.55 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 3.84 Mn |
| Mar 31, 2024 | 1.65 Mn |
| Dec 31, 2023 | 947,000.00 |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 3.29 Mn |
| Mar 31, 2023 | 2.42 Mn |
| Dec 31, 2022 | 2.03 Mn |
| Sep 30, 2022 | 642,000.00 |
| Jun 30, 2022 | 454,000.00 |
| Mar 31, 2022 | 359,000.00 |
| Dec 31, 2021 | 812,000.00 |
| Sep 30, 2021 | 1.41 Mn |